Clinical Trial Search

Primary: Percentage of Participants With Healing of RE Who Were Graded "O" at Week 8 Out of Participants Who Were Graded "A" to "D" at Baseline According to Los Angeles…

Primary: Participant Overall Response Rate (ORR) at 6 Months Includes Complete Remissions, Partial Remission, or Nodule Partial Remissions. — 100 Percentage of Participants

Primary: Collection of Post-treatment Catheterization for Safety — 2 participants

Primary: Trough FEV1 Response [L] After 4 Weeks of Treatment — 0.110; 0.134; 0.143; 0.168 L — p=0.3791

Primary: Pharmacodynamic (PD) Parameter: Adjusted Mean Change in Endogenous Thrombin Potential (ETP) From Day 4 Pre-Infusion (PCC or Placebo) Baseline at Day 4, 30 Minutes Post…

Primary: Ratio of MDSC Concentration in the Blood — 0.7680; 0.7919; 0.9876 ratio from baseline

Primary: Percent Change From Baseline in Mean Lumbar Spine Bone Mineral Density (BMD) at Month 12 — 5.67 percent change — p=<0.0005

Primary: Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16 — 62.8; 72.7; 67.8 Percentage of participants

Primary: Median Change in Percent Ki-67 From Baseline — 0.5; 1.0; 1.0; 1.0 percentage of tumor cells

Primary: Number of Participants With Dye Leakage — 3; 2 participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12) — 75.7; 88.9; 90.8 Percentage of participants

Primary: Effect Site Concentration When Conscious Level Reaches OAAS-3 — 2.3; 2.2; 2.5; 2.2 ug/ml

Primary: Participant Response Rates to Decitabine With or Without Valproic Acid in MDS and AML — 22; 29; 6; 9 Percentage of Participants

Primary: Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) — 0.83; 1.08 ratio: endpoint/baseline (pg/mL)

Primary: Percentage of Participants With Reported Adverse Events (Total Adverse Events, Serious Adverse Events and Death) — 31.3; 0; 27.8; 43.8 Percentage of participants